IceCure Medical Ltd

Equities

ICCM

IL0011224156

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.2 ^USD	+0.84%		-0.83%	+12.15%

Apr. 15	IceCure Medical Seeks FDA Nod For ProSense to Treat Early-Stage Breast Cancer	MT
Apr. 15	IceCure Medical Ltd Submits Final Data to the U.S. Food and Drug Administration Requesting Marketing Authorization for ProSense	CI

IceCure Medical Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023

November 15, 2023 at 08:06 am EST

IceCure Medical Ltd reported earnings results for the nine months ended September 30, 2023. For the nine months, the company reported sales was USD 1.97 million compared to USD 2.15 million a year ago. Net loss was USD 11.66 million compared to USD 13.03 million a year ago.

Basic loss per share from continuing operations was USD 0.255 compared to USD 0.354 a year ago.

Latest news about IceCure Medical Ltd

IceCure Medical Seeks FDA Nod For ProSense to Treat Early-Stage Breast Cancer	Apr. 15	MT
IceCure Medical Ltd Submits Final Data to the U.S. Food and Drug Administration Requesting Marketing Authorization for ProSense	Apr. 15	CI
Transcript : IceCure Medical Ltd, 2023 Earnings Call, Apr 03, 2024	Apr. 03
IceCure Medical Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 03	CI
IceCure Medical Seeks FDA Clearance for Cryoablation Technology	Apr. 02	MT
Icecure Submits FDA Regulatory Filing for New Xsense? Cryoablation System with Cryoprobes	Apr. 02	CI
Alliance Global Partners Adjusts IceCure Medical Price Target to $2.90 From $1.90, Maintains Buy Rating	Mar. 20	MT
IceCure Medical Ltd. Reports Positive Topline Results from ICE3 Cryoablation Breast Cancer Study	Mar. 19	CI
IceCure Medical Ltd. Announces Results from an Independent Study	Mar. 04	CI
Icecure Medical Ltd. Announces New Data from A Preliminary, Independent Breast Cancer Study	Feb. 26	CI
Icecure Medical Ltd. Announces U.S. Food and Drug Administration Has Responded Affirmatively to the Company?s Request for Supervisory Review Under 21 Cfr 10.75 Regarding the Fda?S Prior Denial of Icecure?S De Novo Classification Request for Treating Patients with Early-Stage, Low Risk Breast Cancer	Jan. 30	CI
Sector Update: Health Care Stocks Fall Premarket Tuesday	Jan. 16	MT
IceCure Medical Regains Nasdaq Compliance	Jan. 12	MT
IceCure Medical Ltd. Announces the Publication of a Study Called "Cryoablation Allows the Ultimate De-Escalation of Surgical Therapy for Select Breast Cancer Patients	Dec. 13	CI
IceCure Medical Ltd. Announces Release of a Study in a Series of Independent Studies of ProSense	Nov. 28	CI
Transcript : IceCure Medical Ltd, Q3 2023 Earnings Call, Nov 15, 2023	Nov. 15
IceCure Medical Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	Nov. 15	CI
IceCure Medical Files Appeal with U.S. FDA Requesting a Review of its De Novo Classification for ProSense in Early-Stage Breast Cancer	Nov. 15	CI
IceCure Medical Ltd. Announces in Parallel with the Growing Adoption of ProSense(R)	Nov. 06	CI
Icecure Medical Ltd. Announces Provides Update on Substantial Evidence-Based Data Currently Being Generated by 19 Ongoing Studies Using IceCure Medical's Prosense Cryoablation System	Nov. 06	CI
IceCure Medical Receives Minimum Bid Noncompliance Notice From Nasdaq	Nov. 03	MT
Top Midday Gainers	23-10-02	MT
Sector Update: Health Care Stocks Advancing Late Wednesday Afternoon	23-09-20	MT
Sector Update: Health Care Stocks Rising Wednesday Afternoon	23-09-20	MT
Wall Street Set to Open Wednesday Trading Higher as Investors Await Fed Decision on Interest Rates	23-09-20	MT

Chart IceCure Medical Ltd

Duration

Period

More charts

Company Profile

Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-14 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for IceCure Medical Ltd

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.2 USD

Average target price

3 USD

Spread / Average Target

+150.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
ICECURE MEDICAL LTD	+12.15%	54.88M
THERMO FISHER SCIENTIFIC	+8.07%	219B
DANAHER CORPORATION	+6.59%	183B
INTUITIVE SURGICAL, INC.	+11.26%	133B
BOSTON SCIENTIFIC CORPORATION	+26.57%	108B
EDWARDS LIFESCIENCES CORPORATION	+13.35%	52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-0.62%	48.2B
AGILENT TECHNOLOGIES, INC.	-0.93%	40.37B
GE HEALTHCARE TECHNOLOGIES INC.	+11.54%	39.35B
RESMED, INC.	+26.76%	32.03B

Other Advanced Medical Equipment & Technology